SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Courtesy of Gilead Sciences

86

Gilead Sciences

GILD

The California-based biotech continued its rocket-like ascent in 2015–just two years ago it ranked No. 250 on the 500–due to booming sales of its breakthrough Hepatitis C medications. Those drugs–Sovaldi and Harvoni–which cost a fortune, but also cure a chronic, devastating disease, sparked a national debate on drug pricing. They also drove Gilead’s bottom and top lines in 2015–revenues and profits jumped 31% and 50%, respectively. John Milligan, Gilead’s new CEO faces rockier road in 2016: the competition is stiffer and IP challenges and pricing pressures loom.

CEO

John F. Milligan

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Foster City, CA

Years on Fortune 500 List

8

Employees

8,000

Gilead Sciences is also featured in these fortune lists
Key Financials (last fiscal year)
$ millions% change
Revenues ($M)$32,63931.1%
Profits ($M)$18,10849.6%
Assets ($M)$51,839
Total Stockholder Equity ($M)$18,534
Market Value — as of March 31, 2016 ($M)$124,437
Profit Ratios
Profit as % of Revenues55.5%
Profits as % of Assets34.9%
Profits as % of Stockholder Equity97.7%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)11.91
EPS % Change (from 2014)62.0%
EPS % Change (5 year annual rate)48.3%
EPS % Change (10 year annual rate)39.4%
Total Return
Total Return to Investors (2015)8.7%
Total Return to Investors (5 year, annualized)41.4%
Total Return to Investors (10 year, annualized)22.8%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Gilead Sciences

Why the Fight Against AIDS Still Matters, in One Chart

And why the world needs even more affordable drugs.

Read More →
Pfizer 'In Advanced Talks' to Acquire Medivation for About $14 Billion

Pfizer has agreed to pay a little more than $80 per share for Medivation, a source said.

Read More →
New Poll Shows Millennials Prefer Companies That Give to Charity

Brand reputation isn't necessarily tied to cash giving, however.

Read More →